Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | P4HB | P07237 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KLK7 | P49862 | 1/20 | 0.32 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4750274 | 0.94 | KMT2A (0.40) | KMT2AMAPK1CTSKMAPTP4HB | |
| SCHEMBL2670448 | 0.91 | KMT2A (0.41) | KMT2AMAPK1MAPTP4HBHSD11B1 | |
| SCHEMBL14319760 | 0.91 | KMT2A (0.43) | KMT2AMAPK1CTSKMAPTCPB2 | |
| SCHEMBL2670426 | 0.89 | CYP4F2 (0.40) | KMT2AHSD11B1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2670528 | 0.89 | KMT2A (0.43) | KMT2AMAPK1MAPTHSD11B1CYP3A4 | |
| SCHEMBL2670487 | 0.89 | KMT2A (0.39) | KMT2AMAPK1MAPTP4HBHSD11B1 | |
| SCHEMBL4748042 | 0.89 | KMT2A (0.39) | KMT2AMAPK1CTSKMAPTP4HB | |
| SCHEMBL2670240 | 0.88 | KMT2A (0.38) | KMT2AMAPK1MAPTCPB2 | |
| SCHEMBL4749764 | 0.88 | KMT2A (0.38) | KMT2AMAPK1CTSKMAPTP4HB | |
| SCHEMBL2670213 | 0.86 | KMT2A (0.40) | KMT2AMAPK1MAPTHSD11B1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-22 | — | — | US | disclosed |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2013-01-31 | — | — | US | disclosed |
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | NQO2, QDPR, IL4I1 | KMT2A 2847/4885MAPK1 2614/4885CTSK 4157/4885 |
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | NQO2, QDPR, IL4I1 | KMT2A 2847/4885MAPK1 2614/4885CTSK 4157/4885 |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | NQO2, QDPR, IL4I1 | KMT2A 2847/4885MAPK1 2614/4885CTSK 4157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.